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Abstract: To evaluate whether quantitative PET parameters of motion-corrected 68Ga-DOTATATE
PET/CT can differentiate between intrapancreatic accessory spleens (IPAS) and pancreatic neuroen-
docrine tumor (pNET). A total of 498 consecutive patients with neuroendocrine tumors (NET) who
underwent 68Ga-DOTATATE PET/CT between March 2017 and July 2019 were retrospectively ana-
lyzed. Subjects with accessory spleens (n = 43, thereof 7 IPAS) and pNET (n = 9) were included,
resulting in a total of 45 scans. PET images were reconstructed using ordered-subsets expectation max-
imization (OSEM) and a fully convergent iterative image reconstruction algorithm with ฀-values of 1000
(BSREM1000). A data-driven gating (DDG) technique (MOTIONFREE, GE Healthcare) was applied to
extract respiratory triggers and use them for PET motion correction within both reconstructions. PET
parameters among different samples were compared using non-parametric tests. Receiver operating char-
acteristics (ROC) analyzed the ability of PET parameters to differentiate IPAS and pNETs. SUVmax was
able to distinguish pNET from accessory spleens and IPAs in BSREM1000 reconstructions (p < 0.05).
This result was more reliable using DDG-based motion correction (p < 0.003) and was achieved in both
OSEM and BSREM1000 reconstructions. For differentiating accessory spleens and pNETs with specificity
100%, the ROC analysis yielded an AUC of 0.742 (sensitivity 56%)/0.765 (sensitivity 56%)/0.846 (sensi-
tivity 62%)/0.840 (sensitivity 63%) for SUVmax 36.7/41.9/36.9/41.7 in OSEM/BSREM1000/OSEM +
DDG/BSREM1000 + DDG, respectively. BSREM1000 + DDG can accurately differentiate pNET from
accessory spleen. Both BSREM1000 and DDG lead to a significant SUV increase compared to OSEM
and non-motion-corrected data.
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Impact of PET data driven 
respiratory motion correction 
and BSREM reconstruction 
of 68Ga‑DOTATATE PET/CT 
for differentiating neuroendocrine 
tumors (NET) and intrapancreatic 
accessory spleens (IPAS)
Virginia Liberini 1,3,5*, Fotis Kotasidis2, Valerie Treyer3, Michael Messerli3, Erika Orita3, 
Ivette Engel‑Bicik3, Alexander Siebenhüner4 & Martin W. Huellner3
To evaluate whether quantitative PET parameters of motion‑corrected 68Ga‑DOTATATE PET/CT 
can differentiate between intrapancreatic accessory spleens (IPAS) and pancreatic neuroendocrine 
tumor (pNET). A total of 498 consecutive patients with neuroendocrine tumors (NET) who underwent 
68Ga‑DOTATATE PET/CT between March 2017 and July 2019 were retrospectively analyzed. Subjects 
with accessory spleens (n = 43, thereof 7 IPAS) and pNET (n = 9) were included, resulting in a total of 
45 scans. PET images were reconstructed using ordered‑subsets expectation maximization (OSEM) 
and a fully convergent iterative image reconstruction algorithm with β‑values of 1000  (BSREM1000). A 
data‑driven gating (DDG) technique (MOTIONFREE, GE Healthcare) was applied to extract respiratory 
triggers and use them for PET motion correction within both reconstructions. PET parameters among 
different samples were compared using non‑parametric tests. Receiver operating characteristics 
(ROC) analyzed the ability of PET parameters to differentiate IPAS and pNETs. SUVmax was able to 
distinguish pNET from accessory spleens and IPAs in  BSREM1000 reconstructions (p < 0.05). This result 
was more reliable using DDG‑based motion correction (p < 0.003) and was achieved in both OSEM and 
 BSREM1000 reconstructions. For differentiating accessory spleens and pNETs with specificity 100%, 
the ROC analysis yielded an AUC of 0.742 (sensitivity 56%)/0.765 (sensitivity 56%)/0.846 (sensitivity 
62%)/0.840 (sensitivity 63%) for SUVmax 36.7/41.9/36.9/41.7 in OSEM/BSREM1000/OSEM + DDG/
BSREM1000 + DDG, respectively.  BSREM1000 + DDG can accurately differentiate pNET from accessory 
spleen. Both  BSREM1000 and DDG lead to a significant SUV increase compared to OSEM and non‑
motion‑corrected data.
Abbreviations
AUC  Area under the curve
BMI  Body mass index
BPL  Bayesian penalized likelihood
BSREM  Block sequential regularized expectation maximization
CT  Computed tomography
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CECT  Contrast-enhanced computed tomography
DDG  Data-driven gating
IPAS  Intrapancreatic accessory spleen
MIP  Maximum intensity projection
MR  Magnetic resonance
NET  Neuroendocrine tumor
OSEM  Ordered subset expectation maximization
PCA  Principal component analysis
PET  Positron emission tomography
ROC  Receiver operating characteristic
SiPM  Silicon photomultiplier
SSTR  Somatostatin receptor
SUVmax  Maximum standardized uptake value
TOF  Time of flight
VOI  Volume of interest
Accessory spleens are congenital foci of healthy splenic tissue that are separate from the main body of the 
 spleen1,2. Accessory spleens are relatively common, mostly solitary and have no gender predilection. Their pres-
ence was reported to be as high as 10–30% in postmortem  studies3 and in 45–65% of subjects after  splenectomy4. 
On CT, accessory spleens are seen in approximately 15% of  patients5. Accessory spleens are typically located in 
the splenic hilum (80%) and in the tail of the pancreas (17%), but are also found in other locations, such as the 
greater omentum, the splenic ligament, the small and large intestinal mesentery, the wall of the small intestine, 
the female annex and the  scrotum3,6.
Intrapancreatic accessory spleens (IPAS) appear as a solid contrast-enhancing mass, usually smaller than 
3 cm, located within the tail of the  pancreas7–9. Owing to their morphology and contrast characteristics, they 
may be mistaken for pancreatic tumors, in particular neuroendocrine  tumors10. Both CT and MR imaging have 
limited ability to discriminate pancreatic NET and IPAS because they typically share similar morphology and 
contrast enhancement characteristics. Hence, an accurate diagnosis may avoid unnecessary surgery or biopsy.
Accessory spleens can be diagnosed with Tc-99m-labelled colloids. These colloids are taken up into splenic 
tissue due to phagocytosis in the reticulum-endothelial cells and, therefore, can also identify functioning ectopic 
splenic  tissue11. Tc-99m-labelled heat-damaged red blood cell scintigraphy (Tc-99m-HDRBC) also utilizes retic-
ulum-endothelial cells that decompose damaged red blood  cells12,13. However, the sensitivity of these exams is 
hampered by the small size of most IPAS and by the comparably low resolution of conventional scintigraphy, 
limiting a more widespread use of these techniques.
68Ga-labeled somatostatin analogue such as 68Ga-DOTA-TOC, 68Ga-DOTA-TATE and 68Ga-DOTA-NOC 
PET is the mainstay for the evaluation of the somatostatin receptor (SSTR) status of neuroendocrine neoplasms. 
The biodistribution of somatostatin analogs is characterized by a physiological uptake in several organs, includ-
ing  spleen14 and ectopic splenic tissue. Hence, IPAS may mimic pancreatic neuroendocrine tumors (pNET) and 
cause a false positive finding.
Several retrospective studies assessed radiological imaging characteristics of accessory  spleens15,16. Specific 
reports on 68Ga-DOTA-peptide PET in the literature are limited to individual  cases17–19.
The aim of our study was to evaluate whether quantitative parameters of 68Ga-DOTATATE PET/CT can 
differentiate pNET from accessory spleens, including IPAS. For this purpose, the impact of novel Bayesian 
penalized likelihood reconstruction and respiratory data-driven motion correction of PET on quantitation were 
 investigated20.
Materials and methods
Patient selection. We retrospectively analyzed a cohort of 498 consecutive patients, who underwent a 
clinically indicated PET/CT with 68Ga-DOTATATE for staging/restaging neuroendocrine tumors (NET) at the 
University Hospital of Zurich between March 2017 and July 2019. Only patients with documented willingness to 
the use of their medical data for research were included in this retrospective, observational study. Our study was 
approved by the local ethics committee and was conducted in compliance with ICH-GCP rules and the Decla-
ration of Helsinki. First, all PET/CT scans were reviewed by one nuclear medicine physician. All subjects with 
accessory spleens (28 patients and 38 list mode scans with a total of 43 accessory spleens) were included into the 
study. Intrapancreatic lesions were considered accessory spleens (IPAS) if lesions had been stable for at least two 
years, and in the absence of any abdominal neuroendocrine tumor history (n = 7). CT characteristics of lesions 
were reviewed by one double board-certified radiologist/nuclear medicine physician (Fig. 1). Subjects with pan-
creatic neuroendocrine tumors (pNET), either primary or metastatic, were included only if histopathology was 
available (7 patients and 9 list mode scans with a total of 9 pNET; 2 scans with 1 accessory spleen and 1 pNET 
already included in the accessory spleens cohort and 7 scans with 1 pNET) (Fig. 2).
PET/CT acquisition. All patients underwent an exam on a PET/CT scanner with digital detector read-
out technology equipped with silicon photomultipliers (SiPM) (GE Discovery Molecular Insights—DMI PET/
CT, GE Healthcare, Waukesha, WI). In accordance with the EANM procedure guidelines for PET imaging, the 
injected tracer activity was 132.7 ± 20.9 MBq of 68Ga-DOTATATE (range 81–164 MBq).
After an uptake time of 60 min (range 52–79) and following CT acquisition for attenuation correction (from 
the vertex of the skull to the mid-thighs), PET data were acquired in time-of-flight (TOF) mode, covering the 
same anatomical region of the CT, with 2–3 min/bed position and 6–8 bed positions per patient (23% overlap). 
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After that, following in-house rules for 68Ga-DOTATATE-PET, a contrast-enhanced CT (ceCT) scan was acquired 
(in arterial and venous phase) after intravenous injection of 70 mL of iodinated contrast medium (Iodixanol 
[VISIPAQUE 320]; GE Healthcare) in breath-hold, with tube voltage range 120–140 kV and automated dose 
modulation (range 60–440 mA/slice).
Bayesian penalized likelihood (BPL) reconstruction algorithms. The use of absolute quantitative 
methods for PET/CT requires a fundamental standardization and  harmonization21,22. The precision of quanti-
tative PET metrics depends on the combination of several aspects, including homogeneity of reconstruction 
protocols and data analysis  methods23. Today, ordered subset expectation maximization (OSEM) is the most 
widely used algorithm for clinical PET/CT image  reconstruction24, as clinical standard-of-care method. How-
ever, it is known that the true SUV is consistently underestimated with OSEM owing to early iteration termina-
tion and subsequent under-convergence, which is traded-off against  noise25,26. Bayesian penalized likelihood 
(BPL) reconstruction algorithms, such as block sequential regularized expectation maximization (BSREM—
Q.Clear; GE Healthcare), are increasingly used in clinical routine. Indeed, BSREM increases the accuracy of 
lesion quantitation compared to OSEM by maximizing signal–to-noise ratio (SNR) while achieving almost full 
 convergence27–29.
Figure 1.  68Ga-DOTATOC PET/CT showing an intrapancreatic accessory spleen mimicking a pancreatic 
neuroendocrine tumor. Contrast-enhanced CT image in portal-venous phase showing the lesion in the 
pancreatic tail (a). Contrast-enhanced CT image in arterial phase showing the enhancing lesion in the 
pancreatic tail. The lesion is characterized by mild 68Ga-DOTATATE uptake, more evident in OSEM-DDG (d) 
and BSREM-DDG (f) images (SUVmax 8.6 and 7.6, respectively) compared with OSEM (c) and BSREM (e) 
images without DDG (SUVmax 6.4 and 6.2, respectively). The PET volume of the accessory spleen is smaller 
in OSEM-DDG and BSREM-DDG images (980 mm3 and 814  mm3, respectively) compared with OSEM and 
BSREM images without DDG (1400 mm3 and 1520  mm3, respectively).
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The global strength of the regularization in BSREM (β-value) can be choose and modulate according to the 
dataset of patients being studied, allowing for optimal reconstruction depending on the specific characteristics 
of the radiotracer (i.e.: images with low/high contrast or low/high noise, physiological distribution of the radi-
otracer). In this study, the β-value of 1000 was selected based on previous studies, analyzing the effect on image 
quality and considering both radionuclide properties and scanner  characteristics30–32. In a recent study focusing 
on optimization of image reconstruction for 68Ga-PSMA-11, a similar β-value close to 900 provided an optimal 
tradeoff between signal and  noise33.
Respiratory tracking and correction. Respiratory motion may impact on quantification and qualitative 
evaluation of lesions in the chest and upper abdomen. Since most accessory spleens are found in this region, 
motion tracking and subsequent correction may alter quantitative indexes and hypothetical cut-off values 
Figure 2.  68Ga-DOTATATE PET/CT with a pancreatic neuroendocrine tumor seen on PET/CT image (a) and 
on contrast-enhanced CT image (b), confirmed by biopsy. Transaxial PET/CT images illustrate the impact of 
different reconstruction on morphology, volume and uptake of the neuroendocrine tumor. The lesion is better 
defined and yields higher SUVmax on OSEM-DDG (d) and BSREM-DDG (f) images (SUVmax 13.0 and 12.1, 
respectively) compared with OSEM (c) and BSREM (e) images (SUVmax 11.2 and 10.4, respectively). In this 
case, PET volume of the lesion is increased by DDG reconstruction (2880  mm3 for OSEM-DDG and 3170  mm3 
for BSREM-DDG, respectively), because the severe motion blurring present in the conventional reconstruction 
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between IPAS and pNETs. Traditionally, respiratory motion correction is performed using an external gating 
device positioned on the patient’s abdomen/chest and prescribing a priori the number and location of bed posi-
tions to correct for motion.
Unlike externally driven gating, which usually relies on infrared camera tracking of patient motion, data-
driven gating methods use solely PET raw data in combination with dimensionality reduction techniques, in 
order to extract the respiratory signal. In our study, we used a commercially available DDG algorithm (MOTION-
FREE, GE Healthcare), in combination with a motion correction algorithm (Q.STATIC, GE Healthcare) that 
utilizes the quiescent phase of the respiratory cycle [quiescent period gating (QPG)]34–37.
This technique utilizes a principal component analysis (PCA) to compute the spatiotemporal variation of list 
mode data. The algorithm provides a signal-to-noise measure of respiration-like frequencies within the data, 
denoted as R-value, that is configurable (R-value threshold). The determination of the R-value has a function 
of trigger: the R-value is measured at the end of base acquisition time for each bed position for which motion 
screening was prescribed and is used to make an on-the-fly decision whether motion has been detected. This 
then triggers the data acquisition to automatically be extended according to the prescribed acquisition time 
and data binning scheme used for motion correction (MC)38. In the default protocol, the quiescent phase of the 
respiratory cycle is set to 50% for motion correction, triggering an automatic data acquisition extension equaling 
to double the base acquisition time in order to preserve total count statistics. If data are screened retrospectively 
for motion, then using Q.STATIC with a 50% quiescent phase results in utilizing half the acquired data for MC 
without the ability to extend the acquisition prospectively. Furthermore, as the majority of data included in this 
work were analyzed retrospectively (42 scans for a total of 42 accessory spleens, 6 IPAS and 8 pNET) and not 
acquired prospectively with data acquisition extension, comparisons to non-MC data were performed using half 
the base scan time in order to have comparable datasets with similar count statistics. Scans acquired prospec-
tively (3 scans for a total of 1 accessory spleen, 1 IPA and 1 pNET) was not included in this sub-cohort analysis 
to avoid bias in data analysis. The R-value for triggering motion correction used for this study was R = 10.037.
Image reconstruction. PET image datasets were reconstructed with different settings (all with a 256 × 256 
pixel matrix):
1. OSEM: 3 iterations, 16 subsets, FWHMI of 6.3 mm, 1:4 Z-axis filter and 6.4 mm Gaussian filter with both 
time-of-flight (TOF) and point spread function (PSF) modelling  (OSEMPSF; VUE Point FX with SharpIR, 
GE Healthcare).
2. BSREM (Q.Clear, GE Healthcare) with both TOF and PSF and a β-value of 1000.
For respiratory motion correction, we used the DDG algorithm (MOTIONFREE, GE Healthcare) in combi-
nation with a motion correction algorithm (Q.STATIC, GE Healthcare), using a phase offset of 30% and a phase 
window width of 50%, which are the default parameters supplied by the vendor:
1. BSREM1000-DDG with R = 10.0 + Q.STATIC;
2. OSEM-DDG with R = 10.0 + Q.STATIC.
Quantitative imaging analysis. Quantitative analysis was performed by one reader and PET images were 
segmented using a General Electric AW workstation running PET VCAR software (GE Healthcare, Waukesha, 
WI, USA). The following indices were recorded for each lesion:
1. location,
2. maximum diameter in mm, measured on CT,
3. volume in  mm3, measured both on CT and on PET (PET volume),
4. maximum standard uptake value (SUVmax) and mean standard uptake value (SUVmean).
The volume was measured on CT data with an automatic contouring tool, while on PET was calculated using 
a volume of interest (VOI) including the whole lesion volume, outlined with a 3D semi-automatic contouring 
tool, and applying a threshold set at 41% of  SUVmax21. SUVmax and SUVmean were calculated from the same 
VOIs. Thereby the VOI was automatically propagated and adjusted to cover the lesion volume in all different 
reconstruction sets.
For all patients, a VOI of the spleen was also outlined on PET data and its volume measured in  mm3 along 
with SUVmax and SUVmean. Furthermore, a reference liver ROI was used by drawing a 3  cm3 VOI in the right 
lobe of the liver (parenchymal organ background).
Statistical analyses. All statistical analyses were performed using SPSS version 25.0 (IBM Corporation, 
Armonk, NY,  USA39) and Minitab version 19.0 (Minitab Inc., State College, PA,  USA40). Categorical variables are 
expressed as proportions, and continuous variables are presented as mean ± standard deviation (sd) or median 
(range), depending on the distribution of values. The Pearson correlation coefficient was used to assess the rela-
tionship between SUVmax and diameter (mm) of the accessory spleens. A linear regression equation of diameter 
over SUVmax value was calculated for all accessory spleens. Quantitative PET data (SUVmax and SUVmean) of 
the three samples (all accessory spleens, IPAS and pNETs) were compared in each reconstruction using Mann–
Whitney U-test. P-values were calculated for IPAS versus all accessory spleens, IPAS versus pNET, and pNET 
versus all accessory spleens.
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Parameters (SUVmax, SUVmean and volume) of each sample (all accessory spleens, IPAS, pNETs, and all 
lesions) were compared among different reconstructions using Wilcoxon signed ranks test. The different recon-
structions were compared as follows:
• BSREM1000 versus OSEM;
• BSREM1000-DDG with R = 10.0 + Q.STATIC versus  BSREM1000 half time/bed position  (BSREM1000 1/2);
• OSEM-DDG with R = 10.0 + Q.STATIC versus OSEM half time/bed position (OSEM 1/2);
• BSREM1000-DDG with R = 10.0 + Q.STATIC versus OSEM-DDG with R = 10.0 + Q.STATIC.
A two-tailed p-value of < 0.05 was considered to indicate statistical significance.
The ability of quantitative PET parameters (SUVmax and SUVmean) to differentiate between IPAS and pNETs 
was assessed using receiver operating characteristics (ROC) analysis. An area under the ROC curve (AUC) of 
0.90–1 indicated excellent accuracy, 0.80 to < 0.90 good accuracy, 0.70 to < 0.80 fair accuracy, 0.60 to < 0.70 poor 
accuracy, and AUC 0.50–0.60 failed accuracy. ROC results were considered only if AUC was > 0.7041.
Ethics approval. Our study was approved by the ethics committee of the University Hospital of Zurich and 
was conducted in compliance with ICH-GCP rules and the Declaration of Helsinki.
Informed consent. Only patients with documented willingness to the use of their medical data for research 
and written informed consent for the scientific use of medical data were included.
Results
Out of 498 cases, accessory spleens were detected in 63 PET/CT scans of 63 patients (12.2%). Of these, PET list 
mode data was available in 38 scans (60.3%; mean age 56.4, range 33–83 years). A single accessory spleen was pre-
sent in 33 scans (31 scans with one accessory spleen and 2 scans with one accessory spleen and one pNET), two 
accessory spleens were presents in 5 scans. The majority of accessory spleens (79.1%) were located perisplenic, 
particularly medial to the spleen (55.8%; splenic hilum, gastrosplenic ligament, splenorenal ligament), followed 
by an intrapancreatic location (16.3%; IPAS), and 4.6% were ectopic (splenic vessels and paracolic—Table 1).
68Ga-DOTATATE uptake and size of accessory spleens were correlated, SUVmax of accessory spleens accord-
ing to size measured on OSEM and  BSREM1000 reconstruction is shown in Fig. 3a.
Significant correlations were observed between diameter (mm) and SUVmax of accessory spleens:
• in OSEM reconstruction with  r2 = 0.779, p = 0.001, 95% CI [0.515, 0.853] for Pearson correlation, and a coef-
ficient of 1.266, with standard error equal to 0.167, p = 0.001 and  r2 = 57.21% for the linear regression equation;
Table 1.  Demographic data of study subjects and morphological data of accessory spleens and pNETs (values 
are given as mean ± standard deviation and range) for the entire cohort of patients (43 accessory spleens, 7 
IPAS and 9 pNET).
Demographic data of subjects
BMI, kg/m2 (range) 26.8 ± 4.4 (20.1–36.6)
Injected tracer activity, MBq (range) 132.7 ± 20.9 (81.4–164.4)
Time per bed, s (range) 134.0 ± 21.7 (120.0–180.0)
Scan time post injection, min (range) 60.4 ± 6.2 (52.0–79.0)
Volume of the spleen, mL 174.9 ± 43.4 (81.0–296.0)
Lesion Number, n (%) Maximal diameter (mm)—CT Volume  (mm3)—CT
Accessory spleen—total 43 (100%) 13.5 ± 4.7 (6–31) 1477.3 ± 1807.9 (151–11,200)
Perisplenic 34 (79%) 13.8 ± 5.2 (6–31) 1636.1 ± 2054.8 (151–11,200)
Superior 0 – –
Lateral 0 – –
Inferior 3 (6.9%) 16.7 ± 4.1 (12–20) 2173.4 ± 1684.3 (630–3970)
Posterior 2 (4.6%) 11.5 (11–12) 754.5 (720–789)
Anterior 5 (11.6%) 10.8 ± 5.0 (6–18) 851.8 ± 927.7 (151–2420)
Medial 24 (55.8%) 14.2 ± 5.4 (9—31) 1805.8 ± 2322.2 (333–11,200)
Ectopic 9 (21%) 11.4 ± 3.8 (8–17) 877.2 ± 207.7 (367—1120)
Intrapancreatic 7 (16.3%) 12.3 ± 0.5 (12–13) 932.6 ± 89.9 (859–1120)
Splenic vessels 1 (2.3%) 17.0 1000.0
Colon wall 1 (2.3%) 8.0 367.0
pNET—total 9 (100%) 18.5 ± 3.9 (12–24) 2030.8 ± 977.7 (654–3540)
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• in BSREM reconstruction with  r2 = 0.725, p = 0.001, 95% CI [0.598, 0.885] for Pearson correlation, and a 
coefficient of 1.246, with standard error equal to 0.178, p = 0.001 and  r2 = 53.43% for the linear regression 
equation.
Out of 498 cases, pNET lesions (primary and metastatic) were detected in 9 PET/CT scans (1.8%; mean age 
64.2, range 44–74 years), 2 with 1 accessory spleen and 1 pNET already included in the accessory spleen cohort.
Regarding the sub-cohort of patients retrospectively acquired and analyzed for the DDG reconstructions, 
results of lesion quantitation (42 accessory spleens, 6 IPAS and 8 pNET) with and without DDG (R > 10.0) are 
shown in Fig. 3b–d. In all reconstructions, SUVmax and SUVmean were significantly lower in accessory spleens 
compared to the spleen. P-values of Mann–Whitney U-test of PET/CT parameters (SUVmax and SUVmean) 
among the three samples (all accessory spleens, IPAS and pNETs) in each reconstruction are shown in Fig. 3c,d. 
P-values of Mann–Whitney U-test of PET/CT parameters (SUVmax and SUVmean) among all lesions (all acces-
sory spleens, IPAS and pNETs together) in each reconstruction are given in Table 2.
For the entire sub-cohort, SUVmax and SUVmean were able to distinguish pNET both from all accessory 
spleens and from IPAS, both in OSEM and in BSREM reconstructions, with the only exception of SUVmax of 
IPAS vs. pNET in OSEM. In particular, SUVmax can distinguish:
• Accessory spleens vs. pNET in OSEM (p = 0.024) and BSREM (p = 0.014);
• IPAS vs. pNET in BSREM (p = 0.034).
An even higher level of significance was achieved with DDG (R > 10.0), where SUVmax can distinguish:
• Accessory spleens vs. pNET in both OSEM-DDG and BSREM-DDG (p = 0.002 each);
• IPAS vs. pNET in both OSEM-DDG and BSREM-DDG (p = 0.033 each).
Table 2 shows p-values of PET/CT parameters tested against each other in different reconstructions. Wilcoxon 
signed ranks test showed a significant difference of the following parameters:
• BSREM vs. OSEM: SUVmax (p = 0.001) and SUVmean (p = 0.037) of accessory spleens and SUVmax 
(p = 0.010) of all lesions were higher on BSREM;
• OSEM-DDG (R > 10.0) vs. OSEM ½: SUVmax and SUVmean of both accessory spleens and all lesions were 
higher on OSEM-DDG, while PET volume of both accessory spleens and all lesions (Fig. 4) was smaller on 
OSEM-DDG (all p-values < 0.001);
• BSREM-DDG vs. BSREM ½: SUVmax and SUVmean were higher for accessory spleens (p-values < 0.001 and 
0.005, respectively), IPAS (both p-values < 0.036) and all lesions (both p-values < 0.001) on BSREM-DDG;
• BSREM-DDG vs. OSEM-DDG (R > 10.0): SUVmax of accessory spleens (p < 0.018) and SUVmean of pNET 
(p < 0.042) were higher on BSREM-DDG.
Figure 3.  SUVmax of accessory spleens according to size (CT diameter of the lesions, mm) and spleen 
measured on OSEM and  BSREM1000 reconstruction (a). PET volume  (mm
3) and CT volume (b), SUVmax (c) 
and SUVmean (d) of spleen, accessory spleen, IPAS and pNET among different PET reconstructions in the 
subcohort of exams acquired retrospectively (42 accessory spleens, 6 IPAS and 8 pNET). Significant P-values of 
Wilcoxon signed-ranks test, performed for accessory spleens, IPAS and pNET among different reconstructions, 
are reported in the SUVmax (c) and SUVmean panel (d). Note, for readability, only selected significant p-values 
of relevant comparisons are shown, which support the results reported in the text.
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The relationship between SUVmax and PET volume for accessory spleen, IPAS and pNET separately in each 
reconstruction (OSEM, OSEM-DDG, BSREM and BSREM-DDG) is shown in Fig. 5.
The ability of quantitative PET parameters of 68Ga-DOTATATE PET/CT to differentiate pNET and IPAS as 
well as accessory spleens was assessed using a ROC analysis with and without DDG (Fig. 6).
NET are a heterogeneous group of tumors and the uptake of 68Ga-labeled somatostatin analogue is higher in 
well-differentiated NET compared to poorly-differentiated NET, and correlates strongly with  SSTR2A receptor 
 expression42,43. As shown in Fig. 3a, uptake of accessory spleens was rather homogeneous and was associated 
with the size of these organs. For this reason, we aimed to identify an SUVmax cut-off in each reconstruction 
to discriminate pNET and IPAS with a specificity of 100%, in order to avoid false positives. ROC results were 
considered only if AUC was > 0.70. OSEM-DDG and BSREM-DDG yielded good AUC (all > 0.84), while OSEM 
and BSREM yielded at least fair AUC (all > 0.73).
Cut-offs of SUVmax that discriminate pNET and IPAS with 100% specificity were as follows:
• OSEM: SUVmax 19.7 (sensitivity 67%);
• BSREM: SUVmax 22.5 (sensitivity 67%);
• OSEM-DDG (R > 10.0): SUVmax 28.0 (sensitivity 75%);
Table 2.  P-values of Mann–Whitney U-test of PET/CT parameters comparing the three samples (all 
accessory spleens, IPAS and pNETs) in each reconstruction in the subcohort of exams acquired retrospectively 
(42 accessory spleens, 6 IPAS and 8 pNET), as well as P-values of Wilcoxon signed-ranks test of PET/CT 
parameters of all lesions (42 accessory spleens, 6 IPAS and 8 pNET) among different reconstructions in the 
subcohort of exams acquired retrospectively. All lesion*: p-value was calculated with Wilcoxon signed-ranks 
test. Reconstructions**: p-value was calculated with Mann–Whitney U-test.
PET/CT parameters BSREM1000 vs. OSEM
BSREM1000 (DDG 10.0) vs. 
OSEM (DDG 10.0)
OSEM (DDG 10.0) vs. 
OSEM (1/2)
BSREM1000 (DDG 10.0) vs. 
 BSREM1000 (1/2)
All lesion* (accessory spleen, 
IPAS and pNET)
SUVmax 0.010 0.126 0.001 0.001
SUVmean 0.297 0.482 0.001 0.001
PET volume 0.136 0.152 0.001 0.086
Reconstructions** PET parameters
Intrapancreatic spleen vs all 
accessory spleen
Intrapancreatic spleen vs 
pNET pNET vs all accessory spleen
OSEM
SUVmax 0.166 0.057 0.024
SUVmean 0.121 0.044 0.029
BSREM1000
SUVmax 0.117 0.034 0.014
SUVmean 0.114 0.044 0.018
OSEM DDG 10.0
SUVmax 0.559 0.033 0.002
SUVmean 0.473 0.024 0.003
BSREM1000 DDG 10.0
SUVmax 0.854 0.033 0.002
SUVmean 0.676 0.033 0.003
Figure 4.  68Ga-DOTATATE PET/CT of a patient with an incidental accessory spleen, visible on contrast-
enhanced CT images (a,b). The accessory spleen is better defined with DDG and yields higher SUVmax (30.8 
on OSEM (c), 35.1 on OSEM-DDG (d), 32.4 on BSREM (e) 37.0 on BSREM-DDG (f)) and lower PET volume 
(10,750  mm3 on OSEM, 9320  mm3 on OSEM-DDG, 10,150  mm3 on BSREM 9130  mm3 on BSREM-DDG). 
Furthermore, BSREM-DDG shows better noise characteristics compared to OSEM-DDG.
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Figure 5.  Scatter plots showing the relationship between SUVmax and PET volume of accessory spleens, 
IPAS and pNETs in OSEM (a) and BSREM-DDG (b), respectively, in the sub-cohort of patients retrospectively 
acquired (42 accessory spleens, 6 IPAS and 8 pNET).
Figure 6.  ROC curve of SUVmax and SUVmean for discriminating pNET and accessory spleens with OSEM 
(AUC = 0.742 and p = 0.024 of SUVmax; AUC = 0.734 and p = 0.029 of SUVmean (a)), BSREM (AUC = 0.765 
and p = 0.013 of SUVmax; AUC = 0.755 and p = 0.017 of SUVmean (b)), OSEM-DDG (AUC = 0.846 and 
p = 0.002 of SUVmax; AUC = 0.843 and p = 0.002 of SUVmean (c)) and BSREM-DDG (AUC = 0.846 and 
p = 0.002 of SUVmax; AUC = 0.843 and p = 0.002 of SUVmean (d)) reconstructions in the sub-cohort of patients 
retrospectively acquired (42 accessory spleens, 6 IPAS and 8 pNET).
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• BSREM-DDG (R > 10.0): SUVmax 25.0 (sensitivity 75%);
Cut-offs of SUVmax that discriminate pNET and accessory spleens with 100% specificity were as follows:
• OSEM: SUVmax 36.7 (sensitivity 55%);
• BSREM: SUVmax 41.9 (sensitivity 55%);
• OSEM-DDG (R > 10.0): SUVmax 36.9 (sensitivity 62%);
• BSREM-DDG (R > 10.0): SUVmax 39.1 (sensitivity 75%).
Discussion
Our study sought to investigate whether quantitative PET parameters of 68Ga-DOTATATE-PET/CT can dif-
ferentiate intrapancreatic accessory spleens and pancreatic neuroendocrine tumors.
The major findings of our study are as follows: (1) both SUVmax and SUVmean are able to distinguish pNET 
from accessory spleens and IPAS, (2) SUVmax on the BSREM-DDG reconstruction yields the best results (p-value 
≤ 0.002 for pNET vs. accessory spleens and ≤ 0.033 for pNET vs. IPAS), (3) different SUVmax cut-off between 
pNET and accessory spleens/IPAS were found for each reconstruction, (4) and BSREM-DDG reconstruction 
achieved the best ROC curve result [an SUVmax cut-off > 41.7 identifies a pNET with a specificity of 100% and 
a sensitivity of 75% (AUC 0.840)], (5) SUVmax of accessory spleens is linearily correlated with their volume.
68Ga-labeled somatostatin analogue PET/CT is the mainstay for the evaluation of the somatostatin receptor 
(SSTR) status of neuroendocrine tumors. Our results suggest a possible new indication for the use of 68Ga-DOTA-
peptide PET/CT in clinical routine, confirming the ability of 68Ga-DOTATATE PET/CT to distinguish IPAS and 
pNET. This finding may obviate additional imaging studies (as Tc-99m-labeled colloids or Tc-99m-HDRBC) in 
some cases and prevent unnecessary biopsy and/or surgery in cases of intrapancreatic accessory spleens.
Moreover, the impact of reconstruction algorithms is one of the most relevant factors on the use of absolute 
quantitative methods for PET/CT. In a recent phantom study, Lantos et al. find that BSREM can outperform 
OSEM in terms of contrast recovery and organ uniformity for several PET tracers, included 18F-FDG and 68Ga-
DOTATATE44. Therefore, we evaluated both reconstruction algorithms (OSEM and BSREM with a default β-value 
of 1000, selected based on previous studies) and assessed their impact on quantification.
Results of our study are in line with previously described findings, particularly with the phantom study by 
Lantos et al.44. In our study, Bayesian penalized reconstruction data yielded slightly better results than OSEM dis-
tinguishing pNET from IPAS by SUVmax (p-value ≤ 0.034 for BSREM vs. ≤ 0.057 for OSEM) and for distinguish-
ing pNET from accessory spleens by SUVmax (p-value ≤ 0.014 for BSREM vs. ≤ 0.024 for OSEM). This finding 
could be explained with the fact that the majority of well differentiated pNETs are characterized by significantly 
higher somatostatin receptor expression compared to the physiological uptake in splenic tissue (ectopic or not). 
Previous studies on BSREM reconstruction on lung  cancer31,45,46 showed that lesions with higher uptake tend to 
converge faster than lesions with lower activity. The same holds true for our study, where BSREM reconstruction 
lead to a greater difference between the SUVmax of pNET vs. accessory spleens and/or IPAS compared to OSEM.
Besides the image reconstruction algorithm, PET image quality may also be affected by respiratory motion, 
leading to reduced quantitative accuracy and seemingly increased tumor/lesion volume (Fig. 4). This problem 
affects particularly small lesions in the upper abdomen, such as accessory spleens, IPAS and  pNET47–50.
In our study, DDG increased the ability of PET parameters (SUVmax and SUVmean) to discriminate pNET 
from IPAS (SUVmax p-value ≤ 0.033) and/or accessory spleens (SUVmax p-value ≤ 0.002) both in BSREM and 
OSEM reconstructions.
Furthermore, for all the lesions included in our study, DDG lead to a significant increase in SUVmax and 
SUVmean, both with BSREM and OSEM reconstructions (all p-values ≤ 0.001), while a significant decrease in 
PET volume was only found with OSEM reconstruction (p-value ≤ 0.001). These results are in line with a recent 
study of Catalano et al.51. They stated that motion correction reconstructions reduce the effect of image blurring 
that leads to an underestimation of radiotracer uptake and hence falsely low SUVmax and falsely increased PET 
volume. This finding is important, because BSREM is still not widely available, and because DDG reconstruction 
could be easily done off-line, also from raw data acquired on older systems. However, in other instances, where 
motion blurring might be the dominant blurring factor, DDG might be more useful for BSREM compared to 
OSEM.
These results outline the importance of using a motion correction method to optimize the outcome of PET 
imaging. Besides DDG, other methods allow for motion correction, with the most common methods typically 
relying on external devices for gating. However, their use is often hampered by a comparably complicated setup, 
by technical problems and by time constraints.
The impact of different reconstruction algorithms with or without DDG is highlighted by the ROC results. 
Our study has identified different SUVmax and SUVmean cut-off values for each reconstruction. Furthermore, 
the benefits of both BSREM reconstruction (more accurate lesion quantitation and reduced background noise) 
and motion-corrected data (reduced image blurring) yielded the best results in our study: The most accurate 
SUVmax cut-off value (SUVmax 39.1, AUC 0.846, sensitivity 75% and specificity 100%) to discriminate pNET 
vs. accessory spleens was achieved with BSREM-DDG.
Finally, our study reveals a positive linear correlation between SSTR2-positivity and the size of accessory 
spleens, with larger accessory spleens exhibiting higher SUVmax. Even if this result was expected due to the 
partial volume effect, the differences in SUVmax between different size of accessory spleens (diameter < 10 mm, 
10–20 mm and > 20 mm respectively) highlighted in this study, has an important role to better distinguish IPAS 
from pNET, according to the dimension of the pancreatic lesion under evaluation.
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In fact, IPAS are typically solid enhancing lesions of 1.1–2.5 cm in size, usually not exceeding 3 cm in  size7–9. 
In our study, the maximal diameter of IPAS on CT was 12.3 ± 0.5 mm, while the maximal diameter of accessory 
spleens on CT was 13.5 ± 4.7 (6—31) mm (72% of accessory spleens were 10–20 mm in size). Therefore, the size 
difference between IPAS and accessory spleens might partly explain the higher accuracy of SUVmax cut-offs for 
discriminating pNET from accessory spleens compared to IPAS.
Although the SUVmax of larger IPAS may be in the range of the SUVmax of well differentiated pNETs, this 
may not be so relevant in clinical routine, since IPAS-specific radiological characteristics are easily identified 
in larger lesions (i.e. heterogeneous arterial contrast enhancement of the lesion at and same degree of venous 
contrast enhancement of the  spleen52). On the other hand, the assessment of a pancreatic incidentaloma in the 
pancreatic tail is more challenging with smaller lesions. Moreover, in the last years the incidental discovery of 
pancreatic incidentalomas increased owing to technology advancement as outlined by Vagefi et al. (from 2002 
to 2007, 60.4% vs. 40.3% in previous years; mean diameter 42 mm vs. 56 mm in previous  years53).
In conclusion, an SUVmax > 42 identifies a lesion as pNET with a specificity of 100%, regardless of the recon-
struction technique used.
Some limitations of our study are acknowledged. First, the comparably small sample size may have affected 
our results. Multicenter studies might contribute data from other PET/CT scanners, amplifying the sample size. 
However, careful scanner harmonization is a prerequisite for this purpose. Second, owing to the retrospective 
design and also owing to ethical considerations, there was no histological standard of reference for accessory 
spleens. Instead, morphological imaging characteristics, stability over years and absence of abdominal neuroen-
docrine tumor history was used, which is a reasonable approach in our opinion. However, histopathology served 
as standard of reference for all pNETs in our study. Our study used an R-value threshold of 10 for DDG, and a 
β-value of 1000 for BSREM. Therefore, results of our study are limited to these parameter settings, and other 
settings might yield slightly different results. However, the thrust of our finding (higher SUV with BSREM and 
with DDG) is expected to be preserved.
Conclusion
An SUVmax > 42 identifies a pNET with a specificity of 100%, regardless of the reconstruction technique used. 
DDG-based motion correction increases the ability of PET/CT parameters to discriminate IPAS/accessory 
spleens from pNET. DDG-based motion correction is beneficial particularly for the assessment of small lesions 
that are subject to respiratory motion, also in the upper abdomen.  BSREM1000 leads to a significant increase of 
SUV parameters compared to OSEM, while DDG leads to a significant increase of SUV parameters and reduced 
PET volume compared to reconstructions without DDG. Hence, SUV cut-off values need to be adapted to dif-
ferent reconstruction settings.
Data availability
The datasets used and/or analyzed during the current study are available from the corresponding author on 
reasonable request.
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